Climb Bio (NASDAQ:CLYM – Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Wednesday, May 21st. Analysts expect Climb Bio to post earnings of ($0.15) per share for the quarter.
Climb Bio (NASDAQ:CLYM – Get Free Report) last announced its earnings results on Tuesday, March 25th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. On average, analysts expect Climb Bio to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Climb Bio Stock Performance
Shares of CLYM opened at $1.27 on Wednesday. The stock has a market cap of $85.82 million, a price-to-earnings ratio of -0.60 and a beta of -0.12. The company’s fifty day moving average is $1.27. Climb Bio has a 1-year low of $1.05 and a 1-year high of $9.58.
Climb Bio Company Profile
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Featured Articles
- Five stocks we like better than Climb Bio
- Insider Buying Explained: What Investors Need to Know
- NVIDIA Stock Surges on Bullish News: How High Could It Climb?
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Why Boeing May Be Ready to Take Off After Latest Developments
- Best Stocks Under $10.00
- eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner?
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
